The shift towards selective inhibitors of IDO2 [217,218], dual inhibitors of IDO1 and IDO2 [37] or dual inhibitors of IDO1/2 and TDO [33,35,219] represents a sensible trend toward a definitive assessment of the value of dioxygenase inhibition in cancer. This evidence concerns the gene IDO2 and cancer.